Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 TrialSeptember 3, 2020
Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020August 26, 2020
Madrigal Pharmaceuticals Reports 2020 Second QuarterAugust 6, 2020
Press Release History
Resmetirom is an investigational therapy and has not been approved by the FDA (or any other regulatory authority). Resmetirom
is only available for use in a clinical trial setting (ClinicalTrials.gov NCT03900429 and NCT04197479)
Website Developed by Alan Leff Associates, Inc.